Becton-Dickinson
This article was originally published in The Gray Sheet
Executive Summary
Expects FDA clearance of the FACSort cell sorting instrument, the FACS Vantage flow cytometer, and the FACSCount CD4, CD8 and CD3 cell counter "literally any day," Diagnostic Sector President Walter Miller tells investors May 11 at the Alex. Brown health care seminar in Baltimore. The devices have been on the market for research use since 1992 ("The Gray Sheet" Jan. 11, 1993, p. 28)
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.